254 related articles for article (PubMed ID: 33277368)
21. MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity.
Chinnam M; Xu C; Lama R; Zhang X; Cedeno CD; Wang Y; Stablewski AB; Goodrich DW; Wang X
PLoS Genet; 2022 May; 18(5):e1010171. PubMed ID: 35588102
[TBL] [Abstract][Full Text] [Related]
22. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
23. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
24. Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage.
Tollini LA; Jin A; Park J; Zhang Y
Cancer Cell; 2014 Aug; 26(2):235-47. PubMed ID: 25117711
[TBL] [Abstract][Full Text] [Related]
25. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
Xu C; Fan CD; Wang X
Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081
[TBL] [Abstract][Full Text] [Related]
26. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
27. The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization.
Leslie PL; Ke H; Zhang Y
J Biol Chem; 2015 May; 290(20):12941-50. PubMed ID: 25809483
[TBL] [Abstract][Full Text] [Related]
28. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.
Linke K; Mace PD; Smith CA; Vaux DL; Silke J; Day CL
Cell Death Differ; 2008 May; 15(5):841-8. PubMed ID: 18219319
[TBL] [Abstract][Full Text] [Related]
29. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
[TBL] [Abstract][Full Text] [Related]
30. MDMX exerts its oncogenic activity via suppression of retinoblastoma protein.
Zhang H; Hu L; Qiu W; Deng T; Zhang Y; Bergholz J; Xiao ZX
Oncogene; 2015 Oct; 34(44):5560-9. PubMed ID: 25703327
[TBL] [Abstract][Full Text] [Related]
31. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity.
Ranaweera RS; Yang X
J Biol Chem; 2013 Jun; 288(26):18939-46. PubMed ID: 23671280
[TBL] [Abstract][Full Text] [Related]
32. Mdmx promotes genomic instability independent of p53 and Mdm2.
Carrillo AM; Bouska A; Arrate MP; Eischen CM
Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
[TBL] [Abstract][Full Text] [Related]
33. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
Meulmeester E; Pereg Y; Shiloh Y; Jochemsen AG
Cell Cycle; 2005 Sep; 4(9):1166-70. PubMed ID: 16082221
[TBL] [Abstract][Full Text] [Related]
34. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.
Wu W; Xu C; Ling X; Fan C; Buckley BP; Chernov MV; Ellis L; Li F; Muñoz IG; Wang X
Cell Death Dis; 2015 Dec; 6(12):e2035. PubMed ID: 26720344
[TBL] [Abstract][Full Text] [Related]
35. p53 ubiquitination: Mdm2 and beyond.
Brooks CL; Gu W
Mol Cell; 2006 Feb; 21(3):307-15. PubMed ID: 16455486
[TBL] [Abstract][Full Text] [Related]
36. Critical role for a central part of Mdm2 in the ubiquitylation of p53.
Meulmeester E; Frenk R; Stad R; de Graaf P; Marine JC; Vousden KH; Jochemsen AG
Mol Cell Biol; 2003 Jul; 23(14):4929-38. PubMed ID: 12832478
[TBL] [Abstract][Full Text] [Related]
37. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
38. Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
Garcia D; Warr MR; Martins CP; Brown Swigart L; Passegué E; Evan GI
Genes Dev; 2011 Aug; 25(16):1746-57. PubMed ID: 21852537
[TBL] [Abstract][Full Text] [Related]
39. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.
Uldrijan S; Pannekoek WJ; Vousden KH
EMBO J; 2007 Jan; 26(1):102-12. PubMed ID: 17159902
[TBL] [Abstract][Full Text] [Related]
40. Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7.
Zhao K; Yang Y; Zhang G; Wang C; Wang D; Wu M; Mei Y
EMBO Rep; 2018 Feb; 19(2):305-319. PubMed ID: 29295817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
